Q3 Results 2025: Religare, Gland Pharma, Fortis, Castrol India, Barbeque Nation, others releasing Q3 results today

The company board declared an interim dividend for the Financial Year 2024-25 @ Rs 8.95­ per equity share of face value of Rs 10 each, amounting to Rs 102.52 crore, out of profits of the company for the nine months period ended 31st December, 2024. “Further, the Board of Directors has fixed Friday, 07th February, 2025 as the Record Date for determining the shareholders entitled to receive the Interim Dividend for FY 2024-25,” it said in an exchange filing.

R&D expenses for the period stood at Rs 437 million, 4.3 per cent of revenue.

Srinivas Sadu, Executive Chairman of Gland Pharma, said, “Our Q3 FY25 revenue was at Rs 13,841 million with an EBITDA of Rs 3,600 million, resulting in a 26% EBITDA margin. Notably, our base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39%. We are also excited about the progress of our strategic biologics CDMO collaborations with some of the leading companies in this space. These partnerships open doors to exciting opportunities in the rapidly growing biologics CDMO segment and are expected to generate incremental revenue starting next financial year. Furthermore, the recent conclusion of the USFDA inspections at our Dundigal and Pashamylaram facilities underscores our unwavering commitment to quality and regulatory compliance. We remain focused on driving long-term value creation through strategic partnerships, innovation, and continued investments in new products and technologies.”

Elara Securities said, “Prestige Estate (PEPL IN) results came broadly in line with our expectations. Sustained sales aided in overall presales to Rs 30bn vs our estimates of Rs 33bn in the absence of new launches. Management is confident of achieving a full-year presales target of Rs 240-250bn, driven by ~Rs 300bn of new launches where PEPL is confident of selling 40% of inventory at launch. Profitability in the residential segment is also improving – 9MFY25 residential EBITDA margin at 26% vs 23% in FY24. Core operating cash flow was healthy at ~Rs 9bn covering capex spent on annuity and hospitality assets. Investments in land and stake increases amounted to Rs 24bn, driving QoQ rise in net debt to Rs 60bn. Exit rentals in the annuity portfolio stood at Rs 7.5bn and estimated to increase >4x to Rs 43bn in FY29. Notably, the office segment recorded 4.5mn sqft of leasing in CY24 while average occupancy in office and retail portfolios at ~90% & 99%, respectively.”

Thyrocare Technologies Ltd on Monday posted a profit of Rs 19.10 crore during the third quarter of FY25, up 24.43 per cent in comparison to Rs 15.35 crore during the same period last year. It posted revenue from operations at Rs 165.92 crore, reporting a growth of 23.14 per cent as against Rs 134.74 crore during the third quarter of FY24. The company EBITDA stood at Rs 41.7 crore, up 32.4 per cent YoY.

JM Financial said, “India formulations, specialty segment and a milestone income of USD 45mn led the Q3 performance. Domestic business grew ahead of expectations at 14%. The company’s EM business grew 12% (5% beat), driven by strong underlying market growth. The US business missed JMFe by 8%. It was characterized by growth in specialty sales however lower gx sales and lower lenalidomide contribution QoQ. Global specialty sales grew 17.5% YoY (ex-milestone) as underlying prescription trends remain strong. Leqselvi launch is subject to litigation outcome. However, a strong specialty pipeline which includes Ilumya – PsA indication, newer assets like Fibromun and Otenaproxesul provide a long runway for growth. We expect more such M&A deals as the cash pile rises.”

Alembic Pharmaceuticals Ltd on Monday released its fiscal third quarter earnings report with profit at Rs 138.42 crore, down 23.29 per cent in comparison to Rs 180.45 crore during the same period of previous financial year. It posted revenue from operations at Rs 1,692.74 crore, up 3.81 per cent as against Rs 1,630.57 crore during the third quarter of FY24. The company EBITDA was down 2.1 per cent YoY at Rs 260 crore.

Aditya Birla Capital Ltd on Monday released its fiscal third quarter earnings report with profit at Rs 708 crore, posting a decline of 3.77 per cent in comparison to Rs 735.76 crore during the same quarter of previous financial year. Net Interest Income (NII) stood at Rs 1876 crore, up 7.2 per cent YoY. The company recorded revenue from operations at Rs 9381.35 crore, up 9.28 per cent as against Rs 8584.50 crore during the same quarter of FY24.

KPR Mill Limited on Monday released its fiscal third quarter earnings report with profit at Rs 202.25 crore, posting a growth of 8.12 per cent in comparison to Rs 187.06 crore during the corresponding quarter of previous financial year. It posted revenue from operations at Rs 1529.22 crore, up 23.19 per cent as against Rs 1241.31 crore during the same period of previous financial year. The company EBITDA stood at Rs 302 crore, up 11.3 per cent YoY.

Divi's Labs approved the re-appointment of Dr Kiran S. Divi as Whole-time Director and Chief Executive Officer of the Company for a period of 5 years with effect from April 01, 2025. Dr Kiran S Divi has been the Director on Board of Divi’s Laboratories Limited for over the past 25 years. He officially took on the role of leading Divi’s as the Chief Executive Officer starting January 2020.

Divi's Laboratories Ltd on Monday released its fiscal third quarter earnings report with profit at Rs 589 crore, posting a growth of 64.53 per cent in comparison to Rs 358 crore during the same period of FY24, surpassing estimates. It posted revenue from operations at Rs 2319 crore, up 25.01 per cent as against Rs 1855 crore during the same period of previous financial year. The company EBITDA was up 52 per cent YoY at Rs 743 crore.

According to a CNBC TV18 poll, Divi's Labs was expected to post Q3 revenue at 2287 crore and profit was estimated at Rs 507 crore.

Man Infra said that the company continues to be net-debt free with cash and bank balance of Rs 560 crore at consolidated levels as on Dec-24 providing considerable strength for future growth. MICL have total investment of Rs 1,000+ crore in its real estate projects.

Man Infraconstruction Ltd on Monday posted a profit of Rs 84.03 crore during the third quarter of FY25, reporting a decline of 2.87 per cent in comparison to Rs 86.51 crore during the same period of previous financial year. It recorded revenue from operations at Rs 242.33 crore, marginally higher than Rs 241.76 crore reported during the third quarter of FY24. The company EBITDA was up 4 per cent YoY at Rs 106 crore.

Bandhan Bank reported yet another soft quarter with weakness on several fronts reflecting persistent niggles. Elara Securities said, “The key highlights were: 1) yet another quarter of volatile slippages at >5.5% largely contributed by the MFI segment. Moreover, the bank did write-off Rs 12.7bn, which fed into much higher credit cost, 2) despite this, the SMA pool further swelled up, 3) NIM declined 50bp QoQ, which along with higher opex dragged core profitability, and 4) profitability was cushioned by one-offs. Discussion hereon will be manifold on 1) asset quality outcome, especially in light of persisting concerns on the MFI segment & rise in SMA accounts yet again despite such slippages, and 2) the effects of transition, which will have a nagging impact. There are several moving variables, which are hard to access at the current juncture and may have implications on structural valuation.”

InCred Equities says, “IndusInd Bank (IIB) reported 3QFY25 advances at Rs 3.67tr (+12.2% yoy, +2.7% qoq) with continued weakness in microfinance or MFI lending (-8.9% qoq); however, the sequential fall in retail (+2.9% qoq) and corporate loan (+0.5% qoq) segments indicate an intentional slowdown. Within retail, vehicle financing is already witnessing cyclicity, especially in the demand for commercial vehicles whereas the unsecured retail segment (personal loans/credit cards) has been affected by the macroeconomic slowdown and rising defaults. Though management remains optimistic about normalization of demand from 4QFY25F, considering the adverse macroeconomic trends, we remain skeptical of a quick recovery.”